Sjögren’s syndrome affects roughly 43 to 61 people per 100,000 worldwide, making it one of the more common autoimmune diseases, though far less recognized than conditions like rheumatoid arthritis or lupus. In the United States alone, an estimated 280,000 adults have been diagnosed with primary Sjögren’s, and the true number is likely higher because many cases go unrecognized for years.
Global and U.S. Prevalence Numbers
A large meta-analysis published in the Annals of the Rheumatic Diseases calculated the overall prevalence at about 61 cases per 100,000 people. When the researchers narrowed their analysis to only population-based studies (which tend to be more rigorous), the estimate dropped to around 43 per 100,000. That range translates to roughly 3.4 to 4.8 million people affected globally.
In the United States, the picture gets more complicated. A 2024 prevalence study estimated about 279,684 adults carry a physician diagnosis of primary Sjögren’s. But when those cases were held to stricter clinical confirmation criteria, the number dropped sharply to around 52,383. That five-fold gap highlights a real tension in Sjögren’s epidemiology: the condition is both overdiagnosed in some patients (whose dry eyes or dry mouth stem from other causes) and underdiagnosed in others who never get referred to a rheumatologist in the first place. The number of diagnosed cases is projected to climb to roughly 315,000 by 2034 as the population ages and awareness improves.
Who Gets Sjögren’s Most Often
Sjögren’s syndrome overwhelmingly affects women. Ninety percent of adults diagnosed with the condition are female, and 10 percent are male. This 9-to-1 ratio is among the most skewed of any autoimmune disease and is thought to be linked to the influence of sex hormones on immune regulation. Most people develop symptoms between their late 30s and early 50s, though the disease can appear at any age.
Ancestry plays a role as well. Research published in RMD Open found that primary Sjögren’s was roughly twice as common in non-European populations compared to European ones, though the authors noted that data on race and ethnicity in Sjögren’s remains limited. Much of the existing epidemiological research has been conducted in Europe and North America, so prevalence in other regions may be underestimated simply due to fewer studies.
Primary vs. Secondary Sjögren’s
Sjögren’s comes in two forms. Primary Sjögren’s develops on its own, without any other autoimmune condition present. Secondary Sjögren’s occurs alongside another autoimmune disease, most commonly rheumatoid arthritis, lupus, or scleroderma. The two forms occur at roughly similar frequencies, meaning that for every person who has Sjögren’s in isolation, there’s approximately one more person who has it layered on top of another condition.
This matters for prevalence estimates because many studies only count primary cases. When secondary cases are included, the total number of people living with Sjögren’s-related symptoms is substantially larger than headline figures suggest.
Why So Many Cases Go Undiagnosed
The hallmark symptoms of Sjögren’s, persistent dry eyes and dry mouth, are extremely common in the general population for reasons that have nothing to do with autoimmunity. Medications, aging, dehydration, and screen time all cause dryness. That overlap makes it easy for both patients and doctors to dismiss early Sjögren’s symptoms as unremarkable. On average, it takes about three years from the time symptoms first appear to reach a formal diagnosis, according to Johns Hopkins Medicine.
Three years is actually an improvement from older estimates, which placed the average diagnostic delay closer to five or six years. Increased awareness among dentists and ophthalmologists, who often spot the condition’s effects before a rheumatologist gets involved, has helped shorten that timeline. Still, many people cycle through multiple providers before anyone connects their dry eyes, dry mouth, fatigue, and joint pain into a single diagnosis.
The gap between physician-diagnosed and clinically confirmed cases in the U.S. (roughly 280,000 vs. 52,000) also suggests a different kind of diagnostic problem. Some patients receive a Sjögren’s label based on symptoms alone without meeting the full classification criteria, which require specific blood markers or a salivary gland biopsy. This creates uncertainty in both directions: some diagnosed patients may not truly have the disease, while others with genuine Sjögren’s remain undiagnosed because they never received the right tests.
How Sjögren’s Compares to Other Autoimmune Diseases
To put the numbers in context, Sjögren’s is less common than rheumatoid arthritis (which affects about 1 in 100 people) but more common than lupus (roughly 20 to 70 per 100,000, depending on the population studied). It sits in a middle tier of autoimmune diseases: common enough that most rheumatologists see it regularly, but rare enough that many primary care doctors encounter it only occasionally.
The combination of its moderate prevalence, nonspecific early symptoms, and the lack of a single definitive test means Sjögren’s occupies an unusual space. It is simultaneously one of the most common systemic autoimmune conditions and one of the most underrecognized. If you suspect you have it, a rheumatologist is the specialist best equipped to distinguish Sjögren’s from the many other causes of chronic dryness and fatigue.